CTMX FY 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+42.5% YoY

Gross Profit

$53M100.0% margin

Operating Income

-$101M-190.6% margin

Net Income

-$99M-186.8% margin

EPS (Diluted)

$-1.48

Cash Flow

Operating Cash Flow

-$111M

Free Cash Flow

-$113M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$261M

Total Liabilities

$347M

Stockholders' Equity

-$86M

Cash & Equivalents

$194M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$37M	+42.5%
Gross Profit	$53M	$37M	+42.5%
Operating Income	-$101M	-$116M	+12.7%
Net Income	-$99M	-$116M	+14.3%